In June 2014, Gel-Del Technlogies was acquired by PetVivo Holdings - a technology platform leveraging self-assembly of biocompatible components. With senior management of Gel-Del assuming same role in new entitiy, Gel-Del Technologies Inc had been a biomedical device company making thermoplastic biomaterial technologies designed to mimic the body's tissues using revolutionary and patented protein based fabrication techniques. Gel-Del designed and produced medical devices like cosmetic tissue fillers, blood vessel grafts and implanted oral and particle drug delivery systems than represented radical improvement over then existing FDA-approved products, including many other pipeline products, such as cardiovascular stent and catheter coatings. The firm's developed technology allowed design of biomaterials that are rigid or pliable, biodegrades rapidly or slowly, incorporates other molecules such as drugs, objects such as stents, or acts as a structure for growing new body parts, such as blood vessels. The Company injected and/or implanted their proprietary biomaterial as cosmetic, orthopedic and cardiovascular products into animals with great results over several years. Gel-Del's regenerative injected dermal filler particle biomaterial, CosmetaLife, went through clinical trials for the treatment of facial wrinkles. Implanted products - historically, plastic and metal implant materials - had previously suffered from a material interface with the human body. The chief advantage of Gel-Del's material lay in its enhanced biocompatibility. The biomaterial produces minimal thrombosis, foreign body response or inflammation after implantation, while also providing a tissue-like strength that allows native cellular integration into the material over time. Furthermore, Gel-Del material can be formulated to firmly attach to mucosal tissue to take advantage of enhanced drug absorption, produce a soft, wet attachment that is particularly important for buccal delivery offering the promise of their use to make products or materials leading to major improvements in cosmetic surgery, tissue fillers, cardiovascular devices and drug delivery.
